Antimicrobial prevention and therapy for travelers’ infection

References

• Kozarsky PE, Keystone JS. Introduction to travel medicine. In: Travel Medicine. Keystone JS, Kozarsky PE, Freedman DO, Nothdurft H, Connor BA (Eds). Mosby Elsevier Limited, Oxford, UK 1–3 (2004).
   Google Scholar
• Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travellers. J. Am. Med. Assoc.296, 2234–2244 (2006).
   PubMed Web of Science ®Google Scholar
• Steffen R, Kollaritsch H, Fleischer K. Travelers’ diarrhea in the new millennium: consensus among experts from German-speaking countries. J. Travel Med.10, 38–45 (2003).
   PubMed Web of Science ®Google Scholar
• Van Herck K, Castelli F, Zuckerman J et al. Knowledge, attitude and practices in travel-related infectious diseases: the European Airport Survey. J. Travel Med.11, 3–8 (2004).
   PubMed Web of Science ®Google Scholar
• Steffen R. Epidemiology: morbidity and mortality in travellers. In: Travel Medicine. Keystone JS, Kozarsky PE, Nothdurft HD, Connor BA (Eds). Mosby Elsevier Limited, Oxford, UK 5–12 (2004).
   Google Scholar
• Liese B, Mundt KA. Medical insurance claims associated with international business travel. Occup. Environ. Med.54, 499–503 (1997).
   PubMed Web of Science ®Google Scholar
• Freedmann D, Weld LH, Kozarsky PE et al.; for the Geosentinel Surveillance Network. Spectrum of diseases and relation to place of exposure among ill returned travellers. N. Engl. J. Med.354, 119–130 (2006).
   PubMed Web of Science ®Google Scholar
• Wilson ME, Weld LH, Boggild A et al.; for the Geosentinel Surveillance Network. Fever in returned travellers: results from the Geosentinel Surveillance Network. Clin. Infect. Dis.44, 1560–1568 (2007).
   PubMed Web of Science ®Google Scholar
• Snow RW, Guerra CA, Noor AM, Mynt HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature434, 214–217 (2005).
   PubMed Web of Science ®Google Scholar
• Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet367, 1747–1757 (2006).
   PubMed Web of Science ®Google Scholar
• Wellems TE, Miller LH. Two worlds of malaria. N. Engl. J. Med.349, 1496–1498 (2003).
   PubMed Web of Science ®Google Scholar
• Ryan ET, Kain CK. Health advice and immunizations for travelers. N. Engl. J. Med.342(23), 1716–1725 (2000).
   PubMed Web of Science ®Google Scholar
• Steffen R, Fuchs E, Schildknecht J et al. Mefloquine compared with other malaria chemioprophylactic regimens in tourists visiting East Africa. Lancet341, 1299–1303 (1993).
   PubMed Web of Science ®Google Scholar
• Castelli F, Cabona MG, Brunori A, Carosi G. Imported mosquito: an uninvited guest. Am. J. Trop. Med. Hyg.50, 548–549 (1994).
   PubMed Web of Science ®Google Scholar
• Baldari M, Tanburro A, Sabatinelli G et al. Malaria in Maremma, Italy. Lancet351, 1246–1247 (1998).
   PubMed Web of Science ®Google Scholar
• Jelinek T, Schulte K, Beherens R et al. Imported falciparum malaria in Europe: sentinel surveillance data from European network on surveillance of imported infectious diseases. Clin. Infect. Dis.34, 572–576 (2002).
   PubMed Web of Science ®Google Scholar
• Romi R, Boccolini D, Majori G. Epidemiological trends of imported malaria in Italy 2000–2002. G. Ital. Med. Trop.7, 67–70 (2003).
   Google Scholar
• Thrower Y, Goodyer LI. Application of insect repellents by travelers to malaria endemic areas. J. Travel Med.13, 198–202 (2006).
   PubMed Web of Science ®Google Scholar
• Schoepke A, Steffen R, Gratz N. Effectiveness of personal protection measures against mosquito bites for malaria prophylaxis in travelers. J. Travel Med.5, 188–192 (1998).
   PubMed Web of Science ®Google Scholar
• Rossi I, De Valliere S, Hatz C, Rudin W. Personal protective measures against mosquito and other arthropods bite. Rev. Med. Suisse3(111), 1241–1246 (2007).
   PubMedGoogle Scholar
• Chen LH, Wilson ME, Schlagenhauf P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA297, 2251–2263 (2007).
   PubMed Web of Science ®Google Scholar
• Calleri G, Gobbi F, Beherns RH et al.; and TropNetEurope. Malaria chemoprophylaxis in VFR: a study with the Delphi method. Presented at: 5th European Congress on Tropical Medicine and International Health. Amsterdam, The Netherlands, 24–28 May 2007 (PA159).
   Google Scholar
• McKeage K, Scott LJ. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria. Drugs63, 597–623 (2003).
   PubMed Web of Science ®Google Scholar
• Petersen E. The safety of atovaquone/proguanil in long-term malaria prophylaxis in non-immune adults. J. Travel Med.10(Suppl. 1), 13–15 (2003).
   Google Scholar
• Overbosch D, Schiltuis H, Bienzle U et al. Atovaquone–proguanil versus mefloquine for malaria prophylaxis in non-immune travelers: results from a randomized, double-blind study. Clin. Infect. Dis.33, 1015–1021 (2001).
   PubMed Web of Science ®Google Scholar
• Schwartz E, Bujanover S, Kain K. Genetic confirmation of atovaquone–proguanil resistant Plasmodium falciparum malaria acquired by non-immune traveller to East Africa. Clin. Infect. Dis.37, 450–451 (2003).
   PubMed Web of Science ®Google Scholar
• White NJ. Antimalarial drug resistance. J. Clin. Invest.113, 1084–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Schlagenhauf P, Tschopp A, Johnson R et al.Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomized, double-blind, four-arm study. Br. Med. J.327, 1078–1083 (2003).
   PubMed Web of Science ®Google Scholar
• Baird JK. Effectiveness of antimalarial drugs. N. Engl. J. Med.352(15), 1565–1577 (2005).
   PubMed Web of Science ®Google Scholar
• Matteelli A, Chiodera A, Castelli F, Caligaris S, Minardi C, Carosi G. Failure of mefloquine prophylaxis for malaria in Mozambique. J. Travel Med.2, 260–261 (1995).
   PubMedGoogle Scholar
• Weinke T, Trautmann M, Held T. Neuropsychiatric side effects after the use of mefloquine. Am. J. Trop. Med. Hyg.45, 86–91 (1991).
   PubMed Web of Science ®Google Scholar
• Winstanley P, Beherens R. Malaria prophylaxis with mefloquine: neurological and psychiatric adverse drug reactions. Prescr. J.39, 161–165 (1999).
   Google Scholar
• Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin. Infect. Dis.37, 1659–1667 (2003).
   PubMed Web of Science ®Google Scholar
• Hill HR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis. I. Am. J. Trop. Med. Hyg.75, 402–415 (2006).
   PubMed Web of Science ®Google Scholar
• Crockett M, Kain KC. Tafenoquine: a promising new antimalarial agent. Expert Opin. Investig. Drugs16, 705–715 (2007).
   PubMed Web of Science ®Google Scholar
• Schwartz E, Parise M, Kozarsky P, Cetron M. Delyed onset of malaria. Implications for chemoprophylaxis in travellers. N. Engl. J. Med.349, 1510–1516 (2003).
   PubMed Web of Science ®Google Scholar
• Potasman I, Beny A, Seligmann H. Neuropsychiatric problems in 2,500 long-term young travellers to the tropics. J. Travel Med.7, 5–9 (2000).
   PubMed Web of Science ®Google Scholar
• Von Seidlein L, Milligan P, Pinder M et al. Efficacy of artesunate plus pyrimethamine–sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, control trial. Lancet255, 352–357 (2000).
   Google Scholar
• Adjuik M, Agnamey P, Babiker A et al. Amodiaquine–artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet359, 1365–1372 (2002).
   PubMed Web of Science ®Google Scholar
• International Artemisinin Study Group. Artesunate combinations for treatment of malaria: a meta-analysis. Lancet363, 9–17 (2004).
   PubMed Web of Science ®Google Scholar
• Ruebush TK 2nd, Zegarra J, Cairo J et al. Chloroquine-resistant Plasmodium vivax malaria in Peru. Am. J. Trop. Med. Hyg.69(5), 548–552 (2003).
   PubMed Web of Science ®Google Scholar
• Genton B, Baea K, Lorry K, Ginny M, Wines B, Alpers MP. Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea. PNG Med. J.48(3–4), 141–150 (2005).
   PubMedGoogle Scholar
• Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob. Agents Chemother.48(11), 4075–4083 (2004).
   PubMed Web of Science ®Google Scholar
• Ratcliff A, Siswantoro H, Kenangalem E et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open label randomized comparison. Lancet369, 757–765 (2007).
   PubMed Web of Science ®Google Scholar
• Griffith KS, Lewwis LS, Mali S, Parise ME. Treatment of malaria in the United States. A systematic review. JAMA297, 2264–2277 (2007).
   PubMed Web of Science ®Google Scholar
• Hasugian AR, Purba HLE, Kenagalem E et al. Dihydroartemisinin–piperaquine versus artesunate–amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin. Infect. Dis.44, 1067–1074 (2007).
   PubMed Web of Science ®Google Scholar
• Signorini L, Matteelli A, Castelnuovo F, Castelli F, Oladayo O. Primaquine tolerant P. vivax in an Italian traveller from Guatemala. Am. J. Trop. Med. Hyg.55, 472–473 (1996).
   PubMed Web of Science ®Google Scholar
• Lell B, Faucher JF, Missinou MA et al. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet10(355), 2041–2045 (2000).
   Google Scholar
• Malvy D, Djossou F, Vatan R et al. Experience with the combination atovaquone–proguanil in the treatment of uncomplicated Plasmodium falciparum malaria – report of 112 cases. Med. Trop. (Mars.)62(3), 229–231 (2002).
   PubMedGoogle Scholar
• Patel SN, Kain KC. Atovaquone/proguanil for the prophylaxis and treatment of malaria. Expert Rev. Anti Infect. Ther.3, 849–861 (2005).
   PubMedGoogle Scholar
• Wernsdorfer WH. Coartemether (artemether and lumefantrine): an oral antimalarial drug. Expert Rev. Anti Infect. Ther.2, 181–196 (2004).
   PubMedGoogle Scholar
• van Agtmael M, Bouchaud O, Malvy D et al.; CGP 56697 Study Group. The comparative efficacy and tolerability of CGP 56697 (artemether–lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the tropics to The Netherlands and France. Int. J. Antimicrob. Agents12, 159–169 (1999).
   PubMed Web of Science ®Google Scholar
• Hatz C, Nothdurft HD, Gay F et al. Open-label, uncontrolled multi-centre study of the efficacy and safety of Coartem®/Riamet® in the treatment of acute, uncomplicated P. falciparum malaria in non immune travellers: preliminary results. Presented at: 16th International Congress for Tropical Medicine and Malaria. Marseille, France 11–15 September 2005 (Abstract O-144).
   Google Scholar
• World Health Organization. Severe falciparum malaria. Trans. Royal Soc. Trop. Med. Hyg.94(Suppl. 1), 1–90 (2000).
   PubMed Web of Science ®Google Scholar
• White NJ. The treatment of malaria. N. Engl. J. Med.335, 800–806 (1996).
   PubMed Web of Science ®Google Scholar
• Artemether–Quinine Meta-analysis Study Group. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans. Royal Soc. Trop. Med. Hyg.95, 637–650 (2001).
   PubMed Web of Science ®Google Scholar
• Dondorp A, Nosten F, Stepniewska K, Day N, White N. South East Asian Quinine Artesunate Malaria Trial Group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet366, 717–725 (2005).
   PubMed Web of Science ®Google Scholar
• Lalloo DG, Shingadia D, Pasvol G et al.; for the HPA Advisory Comimittee. Malaria prevention in UK travellers. J. Infect.54, 111–121 (2007).
   PubMed Web of Science ®Google Scholar
• Parola P, Paddock C, Raoult D. Tick-borne rickettsioses around the world: emerging disease challenging old concepts. Clin. Microbiol. Rev.18, 719–756 (2005).
   PubMed Web of Science ®Google Scholar
• Walker DH. Rickettsiae and rickettsial infections: the current state of knowledge. Clin. Infect. Dis.4, S39–S44 (2007).
   Google Scholar
• Walker DH. Rickettsial diseases in travellers. Trav. Med. Inf. Dis.1, 35–40 (2003).
   PubMedGoogle Scholar
• Graham CM, Klain KC. Fever in the returned traveller. Infect. Med.21(2), 83–89 (2004).
   Google Scholar
• Raeber PA, Winteler S. Fever in the returned traveller: remember rickettsial disease. Lancet344, 331 (1994).
   PubMed Web of Science ®Google Scholar
• Rahman A, Tegnell A, Vene S, Giesecke J. Rickettsioses in Swedish travellers, 1997–2001. Scand. J. Infect. Dis.35(4), 247–250 (2003).
   PubMed Web of Science ®Google Scholar
• Jelinek T, Loescher T. Clinical features and epidemiology of tick typhus in travellers. J. Travel Med.8, 57–59 (2001).
   PubMed Web of Science ®Google Scholar
• Jensenius M, Fournier PE. Tick-borne rickettsiosis in international travellers. Int. J. Inf. Dis.8, 139–146 (2004).
   PubMed Web of Science ®Google Scholar
• Parola P, Raoult D. Tropical rickettsiosis. Clin. Dermatol.24, 191–200 (2006).
   PubMed Web of Science ®Google Scholar
• Elston DM. New and emerging infectious diseases. J. Am. Acad. Dermatol.52(6), 1062–1068 (2005).
   PubMed Web of Science ®Google Scholar
• Walker DH. The role of host factors in the severity of spotted fever and typhus rickettsiosis. Ann. NY Acad. Sci.590, 10–19 (1990).
   PubMed Web of Science ®Google Scholar
• Silpapojakul K, Ukkachoke C, Krisanapan S, Silpapojakul K. Rickettsial meningitis and encephalitis. Arch. Intern. Med.151(9), 1753–1757 (1993).
   Google Scholar
• Watt G, Chouriyagune C, Ruangweerayud R et al. Scrub typhus infections poorly responsive to antibiotics in northern Thailand. Lancet348(9020), 86–89 (1996).
   PubMed Web of Science ®Google Scholar
• Raoult D, Maurin M. Rickettsia species. In: Antimicrobial and Vaccines. Yu VL, Merigan TC Jr, Barriere SL (Eds). Williams and Wilkins, MD, USA 568–574 (1998).
   Google Scholar
• Rolain JM, Maurin M, Vetris G, Raoult D. In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials. Antimicrob. Agents Chemother.42, 1537–1541 (1998).
   PubMed Web of Science ®Google Scholar
• Ruiz Beltran R, Herrero Herrero JI, Evaluation of ciprofloxacine and doxycicline in the treatment of Mediterranean spotted fever. Eur. J. Clin. Microb. Infect. Dis.36, 427–431 (1992).
   Google Scholar
• Cascio A, Colomba C, Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial. Clin. Infect. Dis.33(3), 409–411 (2001).
   PubMed Web of Science ®Google Scholar
• Cascio A, Colomba C, Antinori S, Paterson DL, Titone L. Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: a randomized controlled trial. Clin. Infect. Dis.34(2), 154–158 (2002).
   PubMed Web of Science ®Google Scholar
• Ruiz Beltran R, Herrero Herrero JI, Deleterious effect of trimetthoprim–sulfamethoxazole in Mediterranean spotted fever. Antimicrob. Agents Chemother.36, 1342–1344 (1992).
   PubMed Web of Science ®Google Scholar
• Brouqui P, Parola P, Fournier PE, Raoult D. Spotted fever rickettsioses in southern and Eastern Europe. FEMS Immunol. Med. Microbiol.49(1), 2–12 (2007).
   PubMed Web of Science ®Google Scholar
• Purvis JJ, Edwards MS. Doxycicline use for rickettsial disease in pediatric patients. Pediatr. Infect. Dis. J.19, 871–874 (2000).
   PubMed Web of Science ®Google Scholar
• Parola P, Paddock C, Raoult D. Tick-borne bacterial diseases in humans: an emerging infectious threat. Clin. Infect. Dis.32, 897–928 (2001).
   PubMed Web of Science ®Google Scholar
• Castelli F, Pezzoli C, Tomasoni L. Epidemiology of travelers’ diarrhea. J. Travel. Med.8(Suppl. 2), S26–S30 (2001).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Evans DG, Rios N, Cabada FJ, Evans DJ, DuPont MW. Prevention of travelers’ diarrhea with trimethoprim–sulfametoxazole. Rev. Inf. Dis.4, 533–539 (1982).
   PubMedGoogle Scholar
• Sack DA, Kaminski DC, Sack JN et al. Prophylactic doxycycline for travelers’ diarrhea: results of a prospective double-blind study of Peace Corps volunteers in Kenya. N. Engl. J. Med.298, 758–763 (1978).
   PubMed Web of Science ®Google Scholar
• Parry H, Howard AJ, Galpin OH, Hassan SP. The prophylaxis of travelers’ diarrhea: a double-blind placebo controlled trial of ciprofloxacin during a Himalayan expedition. J. Infect.28(3), 337–338 (1994).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD, Ericsson CD, de la Cabada F, Shi K, DuPont MW, Martinez-Sandoval F. Rifaximin, a non-absorbed (<0.5%) antibiotic, prevents travelers’ diarrhea (TD). Presented at: Digestive Disease Week, LA, USA, 15–20 May 2004 (Abstract 104053).
   Google Scholar
• DuPont HL, Jiang Z-D, Okhuysen PC et al. Antibacterial chemoprophylaxis in the prevention of travellers’ diarrhea: evaluation of poorly absorbed oral rifaximin. Clin. Infect. Dis.41(Suppl. 8), S571–S576 (2005).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Ericsson C. Prevention of travelers’ diarrhea. In: Travel Medicine. Keystone J, Kozarsky P, Freedman DO, Nothdurft H, Connor BA (Eds). Mosby Elsevier Limited, Oxford, UK 185–190 (2004).
   Google Scholar
• Ericsson CD. Travelers’ diarrhea. epidemiology, prevention and self-treatment. Infect. Dis. Clin. North Am.12, 285–303 (1998).
   PubMed Web of Science ®Google Scholar
• Gillis JC, Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs49, 467–484 (1995).
   PubMed Web of Science ®Google Scholar
• Ericsson CD. Travelers’ diarrhea. Int. J. Antimicrob. Agents21, 116–124 (2003).
   PubMed Web of Science ®Google Scholar
• Kuschner RA, Trofa AF, Thomas RJ et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin. Infect. Dis.21(3), 536–541 (1995).
   PubMed Web of Science ®Google Scholar
• Hoge CW, Gambel JM, Srijan A, Pitarangsi C, Echeverria P. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin. Infect. Dis.26(2), 341–345 (1998).
   PubMed Web of Science ®Google Scholar
• Reves RR, Johnson PC, Ericsson CD, DuPont HL. A cost–effectiveness comparison of the use of antimicrobial agents for treatment or prophylaxis of travelers’ diarrhea. Arch. Intern. Med.148(11), 2421–2427 (1988).
   PubMedGoogle Scholar
• Gorbach SL, Edelman R. Travelers’ diarrhea: National Institutes of Health Consensus Development Conference. Rev. Inf. Dis.8(Suppl. 2), S109–S233 (1986).
   PubMedGoogle Scholar
• Castelli F, Saleri N, Tomasoni LR, Carosi G. Role of antibiotics in the treatment and prevention of travelers’ diarrhea. Digestion73(Suppl. 1), 109–118 (2006).
   PubMed Web of Science ®Google Scholar
• Ericsson CD, Mattila L. Prevention of traveler’s diarreha. Risk avoidance and chemoprophylaxis. In: Textbook of Travel Medicine and Health (2nd Edition). DuPont HL, Steffen R (Eds). BC Decker, Hamilton, ON, Canada 159–164 (2001).
   Google Scholar
• Connor BA, Landzberg BR. Prevention and treatment of acute traveler’s diarrhea. Infect. Med.21, 18–19 (2004).
   Google Scholar
• Meuris B. Observational study of travelers’ diarrhea. J. Travel Med.2, 11–15 (1995).
   PubMedGoogle Scholar
• Ericsson CD, DuPont HL, Mathewson JJ, West MS, Johnson PC, Bitsura JA. Treatment of traveler’s diarrhea with sulfamethoxazole and trimethoprim and loperamide. JAMA263(2), 257–261 (1990).
   PubMed Web of Science ®Google Scholar
• Ericsson CD. Nonantimicrobial agents in the prevention and treatment of travelers’ diarrhea. Clin. Infect. Dis.41(Suppl. 8), S557–S563 (2001).
   Google Scholar
• Murphy GS, Bodhidatta L, Echeverria P et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann. Intern. Med.118, 582–586 (1993).
   PubMed Web of Science ®Google Scholar
• Echeverria P, Verhaert L, Ulyangco CV et al. Antimicrobial resistance and enterotoxin production among isolates of Escherichia coli in the Far East. Lancet.2(8090), 589–592 (1978).
   PubMed Web of Science ®Google Scholar
• Sack RB, Rahman M, Yunus M, Khan EH. Antimicrobial resistance in organisms causing diarrheal diseases. Clin. Infect. Dis.24(Suppl. 1), S102–S105 (1997).
   PubMed Web of Science ®Google Scholar
• Loescher T, Connor BA. Chapter 18. Clinical presentation and treatment of travelers’ diarrhea. In: Travel Medicine. Keystone J, Kozarsky P, Freedman DO, Nothdurft H, Connor BA (Eds). Mosby Elsevier Limited, Oxford, UK 191–199 (2004).
   Google Scholar
• Adachi JA, Ericsson CD, Jiang ZD et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travellers with acute diarrhea acquired in Mexico. Clin. Infect. Dis.37(9), 1165–1171 (2003).
   PubMed Web of Science ®Google Scholar
• Ericsson CD, DuPont HL, Sullivan P, Galindo E, Evans DG, Evans DJ. Bicozamycin, a poorly absorbable antibiotic, effectively treats diarrhea. Ann. Intern. Med.98, 20–25 (1983).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Ericsson CD, Mathewson JJ, de la Cabada FJ, Conrad D. Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. JAMA267, 1932–1935 (1992).
   PubMed Web of Science ®Google Scholar
• Taylor DN. Poorly absorbed antibiotics for the treatment of travelers’ diarrhea. Clin. Infect. Dis.41(Suppl. 8), S564–S570 (2005).
   PubMed Web of Science ®Google Scholar
• Steffen R, Sack DA, Riopel L et al. Therapy of travelers’ diarrhea with rifaximin on various continents. Am. J. Gastroenterol.98, 1073–1078 (2003).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD, Ericsson CD et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin. Infect. Dis.33(11), 1807–1815 (2001).
   PubMed Web of Science ®Google Scholar
• Taylor DN, Connor BA, Shlim DR. Chronic diarrhea in the returned traveler. Med. Clin. North Am.4, 1033–1052 (1999).
   Google Scholar
• Okhuysen PC. Traveler’s diarrea due to intestinal protozoa. Clin. Infect. Dis.33, 110–114 (2001).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Capsuto EG. Persistent diarrhea in travelers. Clin. Infect. Dis.22, 124–128 (2006).
   Google Scholar
• Ericsson CD, Steffen R. Traveler’s diarrhea due to intestinal protozoa. Clin. Infect. Dis.33, 110–114 (2001).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Preventing travelers’ diarrhea: how to make drinking water safe. Doc. WHO/SDE/WHS/05.07, Geneva, Switzerland (2005).
   Google Scholar
• Medical Letter on Drugs and Therapeutics. Drugs for parasitic infections. Med. Lett. Drugs Therapeut.46, e1–e12 (2004).
   PubMed Web of Science ®Google Scholar
• Shlim D, Hoge C, Rajah R. Persistant high risk of diarrhea among foreigners in Nepal during the first 2 years of residence. Clin. Infect. Dis.29, 613–616 (1999).
   PubMed Web of Science ®Google Scholar
• Herwaldt BL, Ackers ML. An outbreak in 1996 of cyclosporiasis associated with imported raspberries. N. Engl. J. Med.336, 1548–1556 (1997).
   PubMed Web of Science ®Google Scholar
• Lobato MN, Hopewell PC. Mycobacterium tuberculosis infection from countries with a high prevalence of tuberculosis. Am. J. Respir. Crit. Care Med.158, 1871–1875 (1998).
   PubMed Web of Science ®Google Scholar
• Cobelens FGJ, Van Deutekom H, Draayer-Jansen IWE et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tubeculosis endemicity. Lancet356, 461–465 (2000).
   PubMed Web of Science ®Google Scholar
• Steffen R. Health risk for short term travellers. In: Travel Medicine: Proceedings of the First Conference on International Travel Medicine. Stefffen R, Lobel HO, Haworth J, Bradley DJ (Eds). Springer-Verlag, Berlin, Germany 27–36 (1989).
   Google Scholar
• Frame JD, Lange DR, Frankenfield DL. Mortality trends of American missionaries in Africa, 1945–1985. Am. J. Trop. Med. Hyg.46, 686–690 (1992).
   PubMed Web of Science ®Google Scholar
• Matteelli A, Gurtman A, Torresi J, Weld L. Tuberculosis in travellers and long term immigrants. Presented at: 7th conference of the International Society of Travel Medicine. Innsbruck, Austria 27–31 May 2001 (Abstract FC05.05, 88).
   Google Scholar
• Smith PG, Fine PEM. BCG vaccination. In: Clinical Tuberculosis. Chapman and Hall Medical, London, UK 417–431 (1998).
   Google Scholar
• Pai M, Menzies D. The new IGRA and the old TST: making good use of disagreement. Am. J. Respir. Crit. Care Med.175(6), 529–531 (2007).
   PubMed Web of Science ®Google Scholar
• Rieder HL. Risk of travel-associated tuberculosis. Clin. Infect. Dis.33, 1393–1396 (2001).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Tuberculosis and air travel: guidelines for prevention and control. WHO/HTM/TB/2006.363 (2006).
   Google Scholar
• Houk VN, Baker JH, Sorensen K et al. The epidemiology of tuberculosis infection in a close environment. Arch. Environ. Health16, 26–50 (1968).
   PubMed Web of Science ®Google Scholar
• Moore M, Valvay SE, Ihle W et al. A train passenger with pulmonary tuberculosis: evidence of limited transmission during travel. Clin. Infect. Dis.28, 52–56 (1999).
   PubMed Web of Science ®Google Scholar
• Matteelli A, Saleri N. Chapter 56. Respiratory Diseases. In: Travel Medicine. Keystone J, Kozarsky P, Freedman DO, Nothdurft H, Connor B (Eds). Mosby Elsevier Ltd, Oxford, UK 527–538 (2004).
   Google Scholar
• Memish ZA, Osoba AO. International travel and sexually transmitted diseases. Travel Med. Infect. Dis.4, 86–93 (2006).
   PubMedGoogle Scholar
• Matteelli A, Carosi G. Sexually transmitted diseases in travellers. Clin. Infect. Dis.32(7), 1063–1067 (2001).
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Global prevalence and incidence of selected curable sexually transmitted infections. Overview and estimates. WHO/CDS/CSR/EDC/2001.10 (2001).
   Google Scholar